Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings.

A live webcast of the presentation will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231218108214/en/

Media and Investor Relations Contact: Temre Johnson Alpine Immune Sciences, Inc. [e-mail] [e-mail]